Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491118 | 0.88 | POLB (0.44) | MEN1KMT2AMAPTGAAPKM | |
| SCHEMBL7832671 | 0.81 | MEN1 (0.44) | MEN1KMT2AMAPTGAAPKM | |
| SCHEMBL6978569 | 0.81 | MEN1 (0.46) | MEN1KMT2AMAPTGAAPKM | |
| SCHEMBL16315801 | 0.73 | PTGDR2 (0.46) | MEN1KMT2AMAPTGAAPKM | |
| SCHEMBL13233774 | 0.72 | PTGDR2 (0.45) | MEN1KMT2AGAAPKM | |
| SCHEMBL9737582 | 0.67 | MEN1 (0.46) | MEN1KMT2AMAPTGAAPKM | |
| SCHEMBL12659259 | 0.67 | ALDH1A1 (0.46) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL12659307 | 0.67 | POLB (0.50) | MAPTGAAPOLBLMNA | |
| SCHEMBL14609074 | 0.67 | POLB (0.44) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL10699847 | 0.64 | AURKA (0.39) | MEN1KMT2AMAPTGAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844338-B2 | Piperidyindoles as serotonin receptor ligands | ELI LILLY AND COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| US-20030225068-A1 | Piperidyindoles as serotonin receptor ligands | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | disclosed |
| EP-1286992-A1 | PIPERIDYINDOLES AS SEROTONIN RECEPTOR LIGANDS | ELI LILLY AND COMPANY (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001087881-A1 | PIPERIDYINDOLES AS SEROTONIN RECEPTOR LIGANDS | ELI LILLY AND COMPANY (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225068-A1 | Piperidyindoles as serotonin receptor ligands | CNR1, HTR1D, HTR1A | MEN1 4540/4885KMT2A 4688/4885MAPT 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.